StockNews.com cut shares of Tuniu (NASDAQ:TOUR – Get Rating) from a hold rating to a sell rating in a research note issued to investors on Tuesday morning.
Tuniu Trading Up 1.1 %
NASDAQ:TOUR opened at $1.88 on Tuesday. The company has a 50-day moving average price of $2.05 and a 200-day moving average price of $1.38. Tuniu has a 12 month low of $0.46 and a 12 month high of $2.90. The company has a current ratio of 1.43, a quick ratio of 1.43 and a debt-to-equity ratio of 0.01. The stock has a market cap of $243.99 million, a price-to-earnings ratio of -6.96 and a beta of 1.73.
Get Tuniu alerts:Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the business. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Tuniu in the 4th quarter worth about $28,000. Marshall Wace LLP bought a new position in shares of Tuniu in the 4th quarter worth about $122,000. Cantor Fitzgerald L. P. bought a new position in shares of Tuniu in the 3rd quarter worth about $162,000. Two Sigma Investments LP increased its stake in shares of Tuniu by 1,140.7% in the 4th quarter. Two Sigma Investments LP now owns 139,010 shares of the technology company's stock worth $210,000 after acquiring an additional 127,806 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of Tuniu by 4.8% in the 2nd quarter. Renaissance Technologies LLC now owns 360,859 shares of the technology company's stock worth $379,000 after acquiring an additional 16,660 shares in the last quarter. 9.17% of the stock is currently owned by institutional investors.
About Tuniu
(Get Rating)
Tuniu Corp. is an online leisure travel company, which engages in the provision of travel-related services in China. The company offers packaged tours, including organized tours and self-guided tours, and also travel-related services for leisure travelers. Its product portfolio includes organized tours, self-guided tours, and tickets for various domestic and overseas tourist attractions.
Recommended Stories
- Get a free copy of the StockNews.com research report on Tuniu (TOUR)
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Receive News & Ratings for Tuniu Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tuniu and related companies with MarketBeat.com's FREE daily email newsletter.